Accurate Surveillance of SARS-CoV-2 Variants of Concern with an Assay that is Resilient to Genomic Variation

SARS-CoV-2 surveillance efforts are facilitated by technologies that extract the viral genome from the patient sample background. Effective surveillance tools should be able to detect variants that have deviated from the original virus strain. The SARS-CoV-2 NGS Assay—RUO is a hybridization capture-based assay featuring the Twist SARS-CoV-2 Research Panel and Biotia COVID-DX (v1.6) software. Here, we highlight the ability of this assay to detect the SARS-CoV-2 Delta variant in clinical samples, which emerged over a year after the panel’s design.

Covered in this Application Note

Detection and characterization of the SARS-CoV-2 Delta variant in two clinical samples

Coverage of >99% of the genome at 5X or greater after enrichment

Design of the Twist SARS-CoV-2 research panel

Analysis of SARS-CoV-2 genome capture efficiency

Share your details to Get the Application Note

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

Accurate Surveillance of SARS-CoV-2 Variants of Concern with an Assay that is Resilient to Genomic Variation

Related Resources

Methylation Sequencing in Cancer Detection

Harnessing the Power of Surveillance Testing on Small Residential College Campuses